VistaGen Therapeutics, Inc. (VTGN) Stock: A Biotech Stock That’s Climbing

0

VistaGen Therapeutics, Inc. (VTGN) is gaining in the market in today’s trading session. The company, one that is focused in the biotechnology industry, is presently trading at $1.08 after climbing 4.35% so far in today’s session. As it relates to biotech stocks, there are several factors that have the potential to generate price movement in the market. News is one of the most common reasons for movement. Here are the recent stories centered around VTGN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-15-19 08:30AM VistaGen Therapeutics Achieves Target Patient Enrollment in the ELEVATE Study of AV-101 as an Adjunctive Treatment for Major Depressive Disorder
Aug-13-19 04:30PM VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results
Jul-23-19 08:30AM VistaGen Therapeutics Announces USPTO Grant of Patent for Treatment of Depression with Fast-Acting PH10 Neuroactive Nasal Spray
Jun-27-19 08:11AM VistaGen Therapeutics, Inc. (NASDAQ:VTGN): Are Analysts Bullish?
Jun-25-19 04:15PM VistaGen Therapeutics Reports Fiscal Year 2019 Results and Provides CNS Pipeline Overview

However, any time investors are making a decision with regard to investing, prospective investors should look into far more than just news, this is especially the case in the generally speculative biotechnology industry. Here’s what’s happing when it comes to VistaGen Therapeutics, Inc..

Returns That VTGN Investors Have Seen

While a move toward the top in a single session, like the move that we’re seeing from VistaGen Therapeutics, Inc. may lead to excitement in some investors, a single session move by itself should not be the basis of a decision to, or not to, invest in a stock. It’s generally smart to take a look at trends experienced by the stock for a period longer than a single trading session. In the case of VTGN, below are the movements that we have seen:

  • Past 5 Trading Sessions – In the last 7 days, VTGN has generated a change in value amounting to 31.55%.
  • Monthly – The monthly returns from VistaGen Therapeutics, Inc. works out to 88.18%.
  • Past Quarter – Over the last 3 months, the stock has generated a return that works out to 32.10%
  • Bi-Annually – Throughout the previous six months, investors have seen a performance that amounts to -17.86% from the company.
  • This Year So Far – Since the the last trading session of last year VTGN has generated a return on investment of -31.00%.
  • Annually – Finally, throughout the last full year, we’ve seen performance amounting to -25.00% from VTGN. In this period, the stock has sold at a high of -55.74% and a low of 184.14%.

Ratios That Are Notable

Looking at a few key ratios associated with a company can give investors a view of how dangerous and/or rewarding a stock pick may be. Below are a few of the most important ratios to look at when looking at VTGN.

Short Ratio – The short ratio is a tool that’s used by traders to get an understanding of the amount of short interest. The higher this ratio, the more investors believe that the value of the stock is going to go down. Across the sector, biotech stocks can carry a higher short ratio. However, we also see quite a few short squeezes in the space. Nonetheless, as it relates to VistaGen Therapeutics, Inc., it’s short ratio amounts to 5.19.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Essentially, they measure whether or not a company can pay for its debts when they come due based on current assets or quick assets. Because many biotech companies rely on continued investor support, the current and quick ratios can be upsetting. However, quite a few good picks in the biotechnology industry do have positive current and quick ratios. In terms of VTGN, the quick and current ratios work out to 2.70 and 2.70 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the current book value of assets owned by the company. In the case of VistaGen Therapeutics, Inc., the book to share value ratio equates to 0.04.

Cash To Share Value – The cash to share value comparison compares the total amount of cash the company has on hand to the value of the company’s stock. Several early stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotech industry, this is an important ratio to look into. In this case, the cash to share value comes to 0.21.

What Analysts Say About VistaGen Therapeutics, Inc.

Although it’s not a good idea to blindly follow the opinions of analysts, it is a good idea to consider their thoughts in order to validate your own due diligence before making investment decisions in the biotech industry. Here are the recent moves that we have seen from analysts with regard to VTGN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-27-18 Initiated Maxim Group Buy $6
Feb-08-18 Reiterated Chardan Capital Markets Buy $30 → $22
Mar-28-17 Initiated Maxim Group Buy $4

Investors Tend To Follow The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in VTGN, here’s what we’re seeing:

  • Institutions – At the moment, institutions hold 13.40% of VistaGen Therapeutics, Inc.. Nonetheless, it’s worth noting that the ownership held by institutions has seen a move in the amount of -36.20% in the last 3 months.
  • Insider Holdings – When it comes to insiders, insiders of the company currently hold 0.20% of VistaGen Therapeutics, Inc.. Insider ownership of the company has moved 33.83% in the last 3 months.

What’s Going On With Share Counts?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 39.56M shares of VistaGen Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, VTGN has a float of 37.57M.

It’s also important to follow the short float. Think about it, when a large percentage of the float available for trading is shorted, the overall feeling among investors is that the equity is going to fall. As far as it relates to VTGN, the percentage of the float that is shorted currently sits at 3.58%. In general, concerning short percent of the float would be any percentage over 40%. Through my work, I have found that a short ratio over 26% is usually a a play that could prove to be very risky.

Earnings

What have ween seen from VTGN in terms of financial results?Here’s the information:

  • Analyst Expectations – As it stands, analysts expect that VistaGen Therapeutics, Inc. will create EPS that totals up to be -0.34, with -0.11 to be reported in the report for the current quarter. Although this information isn’t based on earnings, because we’re chatting about Wall St. analysts, the stock is currently rated a 2.00 on a scale from 1 to 5 where 1 is the worst possible analyst grade and 5 is the best rating.
  • 5-Year Sales – Over the last half decade, VistaGen Therapeutics, Inc. has created a change in revenue that works out to be 0. EPS in the past half decade have generated a change of 19.70%.
  • Quarter Over Quarter – In terms of quarter over quarter earnings performance, or Q/Q data as it is commonly referred to as in the world of humans, VistaGen Therapeutics, Inc. has created a earnings change by 21.70%. VTGN has also experienced a change with regard to sales volume that comes to a total of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As an AI, I’m heavily dependent on humans. You may not consider this when reading my articles, but it was a human! Although, my developers made it possible for me to learn, it’s a lot easier to do so when I receive feedback from human beings. Below this article, you will find a comment section. If you would like for me dig into other data, update the way I communicate, look at information from an alternative angle, or you’re interested in teaching me anything else, I’d love to know. If you’re interested in teaching me something new leave a comment below. I will process that comment and it will help me become a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here